Trial reportThe Lancet. Oncology2019
Erratum issued 4 registry-linked trialsOpen access · greenAbstract readClinical Trial
In one paragraph
Trial report in The Lancet. Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 4 registered trials, which are not on this map. Cited by 227 papers, 8 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
227citing papers in PubMed, 8 pooled it
49.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Single Center Trial to Compare 68Ga-PSMA-11 and Axumin PET/CT (18F-Fluciclovine) for Restaging Prostate Cancer Patients With Biochemical Recurrence After Radical Prostatectomy
68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer
Prostate-Specific Membrane Antigen (PSMA) Guided Approach for bIoCHEmical Relapse After Prostatectomy- A Prospective Observational Study-PSICHE
NCT05936658 phase3active not recruitingnot on this mapstarted 2023, after this paper: background citation
A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer
Who cites it
227 citing papers in PubMed, 8 syntheses or guidelines pooled it, 460 citations in OpenAlex.
- Comparative Detection Performance of PSMA and Non-PSMA PET Tracers in Recurrent and Primary Prostate Cancer: A Systematic Review and Network Meta-Analysis.Clinical nuclear medicine · 2026Pooled it
- PSMA PET-guided intensification of postprostatectomy salvage radiotherapy for prostate cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.European journal of nuclear medicine and molecular imaging · 2023Guideline
- Pooled it
- Pooled it
- Efficacy and safety of salvage radiotherapy combined with endocrine therapy in patients with biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis of randomized controlled trials.Frontiers in oncology · 2022Pooled it
- Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis.European journal of nuclear medicine and molecular imaging · 2021Pooled it
- The Diagnostic Role ofFrontiers in oncology · 2021Pooled it
- [European journal of nuclear medicine and molecular imaging · 2026Trial
- The German Cancer Consortium (DKTK) multi-center prospective phase 1/2European journal of nuclear medicine and molecular imaging · 2026Trial
- [European urology · 2026Trial
- Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy.International journal of radiation oncology, biology, physics · 2025Trial
- Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Trial
- Trial
- Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial.JAMA oncology · 2023Trial
- The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.Lancet (London, England) · 2022Trial
- Salvage Radiotherapy Management Decisions in Postprostatectomy Patients with Recurrent Prostate Cancer Based onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Diagnostic Performance ofClinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Trial
- Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Trial
167 more citing papers are in PubMed but not listed here.
Corrections and comments
Authors and funding
22 authors at 10 institutions in 5 countries.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: jcalais@mednet.ucla.edu.
Francesco CeciAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; Nuclear Medicine, Department of Medical Sciences, University of Turin, Turin, Italy.
Matthias EiberAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Munich, Germany.
Thomas A HopeDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.
Michael S HofmanMolecular Imaging and Nuclear Medicine Therapeutics, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
Christoph RischplerDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Tore Bach-GansmoDepartment of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway.
Cristina NanniMetropolitan Nuclear Medicine, S Orsola-Malpighi University Hospital, Bologna, Italy.
Bital Savir-BaruchDivision of Nuclear Medicine, Department of Radiology, Loyola University Medical Center, Maywood, IL, USA.
David ElashoffJonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA; Department of Medicine Statistics Core, University of California Los Angeles, Los Angeles, CA, USA.
Tristan GroganDepartment of Medicine Statistics Core, University of California Los Angeles, Los Angeles, CA, USA.
Magnus DahlbomAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Roger SlavikAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.
Jeannine GartmannAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Kathleen NguyenAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Vincent LokAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Hossein JadvarDivision of Nuclear Medicine, Department of Radiology, University of Southern California, Los Angeles, CA, USA.
Amar U KishanInstitute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA; Department of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Matthew B RettigInstitute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA; Department of Urology, University of California Los Angeles, Los Angeles, CA, USA.
Robert E ReiterInstitute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA; Department of Urology, University of California Los Angeles, Los Angeles, CA, USA.
Wolfgang P FendlerAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA; Institute of Urologic Oncology, University of California Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · USLoyola University Medical Center · USOslo University Hospital · NOPoliclinico S.Orsola-Malpighi · ITTechnical University of Munich · DEUniversity of California, San Francisco · USUniversity of Duisburg-Essen · DEUniversity of Melbourne · AUUniversity of Southern California · USUniversity of Turin · IT
Funding
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MYLES G COCKBURN · 1985 to 2026
$181.4MWomen's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2MQualification and Harmonization of PET/MRI for Cancer Clinical TrialsR01CA212148 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS, LAFOREST, RICHARD ANDRE · 2017 to 2022
$2.7MPilot Human Studies of FMAU PET in Prostate CancerR21EB017568 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JADVAR, HOSSEIN · 2015 to 2016
$433kNCI NIH HHS P30 CA014089NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA212148NIBIB NIH HHS R21 EB017568
Abstract
backgroundNational Comprehensive Cancer Network guidelines consider
methodsThis was a prospective, single-centre, open-label, single-arm comparative study done at University of California Los Angeles (Los Angeles, CA, USA). Patients older than 18 years of age with prostate cancer biochemical recurrence after radical prostatectomy and PSA levels ranging from 0·2 to 2·0 ng/mL without any prior salvage therapy and with a Karnofsky performance status of at least 50 were eligible. Patients underwent
findingsBetween Feb 26, 2018, and Sept 20, 2018, 143 patients were screened for eligibility, of whom 50 patients were enrolled into the study. Median follow-up was 8 months (IQR 7-9). The primary endpoint was met; detection rates were significantly lower with
interpretationWith higher detection rates, PSMA should be the PET tracer of choice when PET-CT imaging is considered for subsequent treatment management decisions in patients with prostate cancer and biochemical recurrence after radical prostatectomy and low PSA concentrations (≤2·0 ng/mL). Further research is needed to investigate whether higher detection rates translate into improved oncological outcomes.
fundingNone.
Indexed as
AgedCarboxylic AcidsContrast MediaCyclobutanesEdetic AcidGallium IsotopesGallium RadioisotopesHumansMaleMiddle AgedNeoplasm Recurrence, LocalOligopeptidesPositron Emission Tomography Computed TomographyProspective StudiesProstatectomyProstate-Specific AntigenCarboxylic AcidsContrast MediaCyclobutanesEdetic Acidfluciclovine F-18gallium 68 PSMA-11Gallium IsotopesGallium RadioisotopesOligopeptidesProstate-Specific Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03515577ClinicalTrials.gov
NCT04854369ClinicalTrials.gov
NCT05022914ClinicalTrials.gov
NCT05936658ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.